Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Total Current Liabilities (2024 - 2025)

Xilio Therapeutics' Total Current Liabilities history spans 2 years, with the latest figure at $56.4 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 48.34% year-over-year to $56.4 million; the TTM value through Sep 2025 reached $56.4 million, up 48.34%, while the annual FY2024 figure was $27.3 million, N/A changed from the prior year.
  • Total Current Liabilities for Q3 2025 was $56.4 million at Xilio Therapeutics, up from $53.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $56.4 million in Q3 2025 and bottomed at $27.3 million in Q4 2024.